Cargando…

Sex‐dependent least toxic timing of irinotecan combined with chronomodulated chemotherapy for metastatic colorectal cancer: Randomized multicenter EORTC 05011 trial

The least toxic time (LTT) of irinotecan varied by up to 8 hours according to sex and genetic background in mice. The translational relevance was investigated within a randomized trial dataset, where no LTT stood out significantly in the whole population. 130 male and 63 female eligible patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Innominato, Pasquale F., Ballesta, Annabelle, Huang, Qi, Focan, Christian, Chollet, Philippe, Karaboué, Abdoulaye, Giacchetti, Sylvie, Bouchahda, Mohamed, Adam, René, Garufi, Carlo, Lévi, Francis A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7300418/ https://www.ncbi.nlm.nih.gov/pubmed/32319740 http://dx.doi.org/10.1002/cam4.3056

Ejemplares similares

Efficacy and safety of chronomodulated irinotecan, oxaliplatin, 5‐fluorouracil and leucovorin combination as first‐ or second‐line treatment against metastatic colorectal cancer: Results from the International EORTC 05011 Trial
por: Innominato, Pasquale F., et al.
Publicado: (2020)

Circadian rest‐activity rhythm as an objective biomarker of patient‐reported outcomes in patients with advanced cancer
por: Innominato, Pasquale F., et al.
Publicado: (2018)

Undetectable RAS-Mutant Clones in Plasma: Possible Implication for Anti-EGFR Therapy and Prognosis in Patients With RAS-Mutant Metastatic Colorectal Cancer
por: Bouchahda, Mohamed, et al.
Publicado: (2020)

Time-Dependent Efficacy of Checkpoint Inhibitor Nivolumab: Results from a Pilot Study in Patients with Metastatic Non-Small-Cell Lung Cancer
por: Karaboué, Abdoulaye, et al.
Publicado: (2022)

Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228)
por: Lévi, Francis, et al.
Publicado: (2017)

A phase II study of irinotecan plus chronomodulated oxaliplatin, 5-fluorouracil and folinic acid in advanced colorectal cancer patients
por: Garufi, C, et al.
Publicado: (2003)

Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial
por: Garufi, C, et al.
Publicado: (2010)

Optimizing circadian drug infusion schedules towards personalized cancer chronotherapy
por: Hill, Roger J. W., et al.
Publicado: (2020)

Systems Chronotherapeutics
por: Ballesta, Annabelle, et al.
Publicado: (2017)

Tumor Growth Rate Determines the Timing of Optimal Chronomodulated Treatment Schedules
por: Bernard, Samuel, et al.
Publicado: (2010)

Circadian and chemotherapy-related changes in urinary modified nucleosides excretion in patients with metastatic colorectal cancer
por: Dulong, S., et al.
Publicado: (2021)

A Combined Experimental and Mathematical Approach for Molecular-based Optimization of Irinotecan Circadian Delivery
por: Ballesta, Annabelle, et al.
Publicado: (2011)

Development and characterization of chronomodulated drug delivery system of captopril
por: Patil, Archana S, et al.
Publicado: (2011)

Chronomodulated drug delivery system of urapidil for the treatment of hypertension
por: Chaudhary, Sona S., et al.
Publicado: (2015)

Clinical Relevance of the First Domomedicine Platform Securing Multidrug Chronotherapy Delivery in Metastatic Cancer Patients at Home: The inCASA European Project
por: Innominato, Pasquale F, et al.
Publicado: (2016)

Phase 1–3 of the cross‐cultural development of an EORTC questionnaire for the assessment of sexual health in cancer patients: the EORTC SHQ‐22
por: Oberguggenberger, Anne Sophie, et al.
Publicado: (2018)

Design of Chronomodulated Drug Delivery System of Valsartan: In Vitro Characterization
por: Sokar, M., et al.
Publicado: (2015)

Phase I pharmacological study of continuous chronomodulated capecitabine treatment
por: Roosendaal, Jeroen, et al.
Publicado: (2020)

Chronomodulated Drug Delivery System of Salbutamol Sulphate for the Treatment of Nocturnal Asthma
por: Qureshi, J., et al.
Publicado: (2008)

Clocking Epilepsies: A Chronomodulated Strategy-Based Therapy for Rhythmic Seizures
por: Sun, Sha, et al.
Publicado: (2023)

A retrospective study of patient-tailored FOLFIRINOX as a first-line chemotherapy for patients with advanced biliary tract cancer
por: Ulusakarya, Ayhan, et al.
Publicado: (2020)

Extended RAS Analysis of the Phase III EPIC Trial: Irinotecan + Cetuximab Versus Irinotecan as Second‐Line Treatment for Patients with Metastatic Colorectal Cancer
por: Sobrero, Alberto, et al.
Publicado: (2020)

A mathematical model of the circadian clock and drug pharmacology to optimize irinotecan administration timing in colorectal cancer
por: Hesse, Janina, et al.
Publicado: (2021)

Compression-coated pulsatile chronomodulated therapeutic system: QbD assisted optimization
por: Aldawsari, Hibah M., et al.
Publicado: (2022)

Circadian optimisation of irinotecan and oxaliplatin efficacy in mice with Glasgow osteosarcoma
por: Granda, T G, et al.
Publicado: (2002)

Comparing Conventional Chemotherapy to Chronomodulated Chemotherapy for Cancer Treatment: Protocol for a Systematic Review
por: Kilgallen, Aoife B, et al.
Publicado: (2020)

Chronomodulated Administration of Chemotherapy in Advanced Colorectal Cancer: A Systematic Review and Meta-Analysis
por: Nassar, Ahmed, et al.
Publicado: (2023)

PEPCOL: a GERCOR randomized phase II study of nanoliposomal irinotecan PEP02 (MM‐398) or irinotecan with leucovorin/5‐fluorouracil as second‐line therapy in metastatic colorectal cancer
por: Chibaudel, Benoist, et al.
Publicado: (2016)

Phase I study of intermittent and chronomodulated oral therapy with capecitabine in patients with advanced and/or metastatic cancer
por: Santini, Daniele, et al.
Publicado: (2006)

Association of UGT1A1*6 polymorphism with irinotecan-based chemotherapy reaction in colorectal cancer patients: a systematic review and a meta-analysis
por: Zhu, Xiaoyun, et al.
Publicado: (2020)

EORTC SPECTA‐AYA: A unique molecular profiling platform for adolescents and young adults with cancer in Europe
por: de Rojas, Teresa, et al.
Publicado: (2019)

Validation and Reliability Testing of the EORTC QLQ-NMIBC24 Questionnaire Module to Assess Patient-reported Outcomes in Non–Muscle-invasive Bladder Cancer
por: Blazeby, Jane M., et al.
Publicado: (2014)

Relevance of a Mobile Internet Platform for Capturing Inter- and Intrasubject Variabilities in Circadian Coordination During Daily Routine: Pilot Study
por: Komarzynski, Sandra, et al.
Publicado: (2018)

Combination chemotherapy consisting of irinotecan, etoposide, and carboplatin for refractory or relapsed neuroblastoma
por: Imaya, Masayuki, et al.
Publicado: (2022)

Efficacy of Chronomodulated Chemotherapy for Palliation of Hematemesis in Inoperable Gastric Cancer: A Single-Institutional Retrospective Study
por: Biswas, Satadru, et al.
Publicado: (2020)

Quality of Life in Male Breast Cancer: Prospective Study of the International Male Breast Cancer Program (EORTC10085/TBCRC029/BIG2-07/NABCG)
por: Schröder, Carolien P, et al.
Publicado: (2023)

Validation of EORTC, CUETO, and EAU risk stratification in prediction of recurrence, progression, and death of patients with initially non–muscle‐invasive bladder cancer (NMIBC): A cohort analysis
por: Jobczyk, Mateusz, et al.
Publicado: (2020)

Cetuximab and Irinotecan With or Without Bevacizumab in Refractory Metastatic Colorectal Cancer: BOND-3, an ACCRU Network Randomized Clinical Trial
por: Lipsyc-Sharf, Marla, et al.
Publicado: (2022)

Avapritinib in Patients With Advanced Gastrointestinal Stromal Tumors Following at Least Three Prior Lines of Therapy
por: George, Suzanne, et al.
Publicado: (2021)

Prospective assessment of the predictive value of the BRCA1 gene status in sarcoma patients treated with trabectedin: an updated analysis of the EORTC 62091 trial
por: Italiano, Antoine, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_25ulufg2k93ugcpt3k3i599s9d